Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve a) The Audited Standalone ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has informed stock exchanges that its Board of Directors will meet on Monday, May 12, 2025. The Board will consider and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2025, along with the balance sheet, cash flow statement, and audit report. It will also approve the audited financial statements for FY25 and consider recommending a final dividend, if any. The trading window for designated persons has been closed since April 1, 2025 and will reopen 48 hours after the results are announced.
This is a routine pre-results announcement and signals that Q4 and FY25 earnings, plus the final dividend decision, are due on May 12. Investors should watch for the actual results, dividend declaration, and any modified audit opinion, as these could move the stock.